| P2093 | author name string | Jiajie Chen | |
| | Kunmei Ji | |
| | Jiayun Hu | |
| | Jinlu Sun | |
| | Lanlan Ye | |
| | Zelang Cai | |
| P2860 | cites work | Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice | Q24604440 |
| | Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 |
| | CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation | Q24678846 |
| | The crystal structure of IgE Fc reveals an asymmetrically bent conformation | Q27639182 |
| | A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma | Q27689386 |
| | Humanization of an antibody directed against IgE | Q28261992 |
| | Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases | Q28294789 |
| | Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease | Q30276181 |
| | Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab | Q33362984 |
| | Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin | Q33588223 |
| | Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells | Q33850604 |
| | Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells. | Q34093487 |
| | Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells | Q34148448 |
| | Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. | Q34414866 |
| | Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials | Q88010602 |
| | Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. | Q51722262 |
| | Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. | Q52936508 |
| | IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. | Q54417521 |
| | Measurement of IgE antibody by an antigen-binding assay: correlation with PK activity and IgG and IgA antibodies to allergens | Q67318522 |
| | Conformations of IgE bound to its receptor Fc epsilon RI and in solution | Q67902731 |
| | Involvement of Fc epsilon RII/CD23 and L-arginine dependent pathway in IgE-mediated activation of human eosinophils | Q72159530 |
| | Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII | Q73514724 |
| | Feasibility and safety of granulocytapheresis in Crohn's disease: a prospective cohort study | Q82448391 |
| | Natural IgE production in the absence of MHC Class II cognate help | Q82872924 |
| | Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody | Q83275619 |
| | Structural changes in the lectin domain of CD23, the low-affinity IgE receptor, upon calcium binding | Q83964234 |
| | Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab | Q84070032 |
| | Allergic rhinitis | Q84587622 |
| | The Biochemical Properties of Antibodies and Their Fragments | Q85566755 |
| | A novel, nonanaphylactogenic, bispecific IgE-CD3 antibody eliminates IgE(+) B cells | Q87023255 |
| | Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production | Q34427691 |
| | Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. | Q34509694 |
| | Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects | Q34782224 |
| | Selective IgE deficiency and cardiovascular diseases | Q35516115 |
| | Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects | Q35918874 |
| | Spotlight on omalizumab in allergic asthma | Q35967238 |
| | Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council | Q36358191 |
| | The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors | Q36377480 |
| | Self-reactive IgE exacerbates interferon responses associated with autoimmunity. | Q36479577 |
| | The role of the mast cell in the pathophysiology of asthma | Q36496382 |
| | A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma | Q36700648 |
| | Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. | Q36870059 |
| | The mast cell and allergic diseases: role in pathogenesis and implications for therapy | Q37010493 |
| | Prevalence, severity and risk factors of allergic disorders among people in south India | Q37025318 |
| | IgE-Related Chronic Diseases and Anti-IgE-Based Treatments | Q37554168 |
| | Emerging role of human basophil biology in health and disease | Q37584453 |
| | Immunoadsorption in dermatology | Q37668084 |
| | Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy. | Q37714270 |
| | Immunoadsorption in dermatology | Q38027895 |
| | Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study. | Q38396322 |
| | Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature. | Q38754492 |
| | From IgE to Omalizumab | Q38793428 |
| | CTLA4Fcε, a novel soluble fusion protein that binds B7 molecules and the IgE receptors, and reduces human in vitro soluble CD23 production and lymphocyte proliferation. | Q38800276 |
| | Gene Therapy for the Treatment of Primary Immune Deficiencies | Q38801423 |
| | Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody | Q38811111 |
| | Targeting Mast Cells and Basophils with Anti-FcεRIα Fab-Conjugated Celastrol-Loaded Micelles Suppresses Allergic Inflammation. | Q38824173 |
| | Role of IgE in autoimmunity | Q38855413 |
| | Frequency analysis of IgE-secreting B lymphocytes in persons with normal or elevated serum IgE levels | Q39137883 |
| | Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses | Q39761643 |
| | Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation | Q40207449 |
| | Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes | Q41289480 |
| | Dynamic conformations compared for IgE and IgG1 in solution and bound to receptors | Q41607659 |
| | A new isoform of human membrane-bound IgE | Q41645058 |
| | Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma | Q44841358 |
| | Addendum: IgE+ memory B cells and plasma cells generated through a germinal-center pathway. | Q45405549 |
| | Trimolecular complex formation of IgE, Fc epsilon RI, and a recombinant nonanaphylactic single-chain antibody fragment with high affinity for IgE. | Q46063437 |
| | Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor | Q46889515 |
| | Food and drug administration approval process for dermatology drugs in the United States | Q48301926 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 27 | |
| P577 | publication date | 2018-07-18 | |
| P1433 | published in | Clinical and translational allergy | Q27724017 |
| P1476 | title | Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells | |
| P478 | volume | 8 | |